Advertisement

Atorvastatin Tablets

[16 September 2014]

Products Affected - Description

Atorvastatin tablets, Ranbaxy
10 mg, 90 count (NDC 63304-0827-90)
10 mg, 500 count (NDC 63304-0827-05)
20 mg, 90 count (NDC 63304-0828-90)
20 mg, 500 count (NDC 63304-0828-05)
40 mg, 90 count (NDC 63304-0829-90)
40 mg, 500 count (NDC 63304-0829-05)
80 mg, 90 count (NDC 63304-0830-90)
80 mg, 500 count (NDC 63304-0830-05)
 
Atorvastatin tablets, Sandoz
40 mg, 90 count (NDC 00781-5384-92)

Reason for the Shortage

  • In November 2012, Ranbaxy voluntarily recalled 41 lots of atorvastatin tablets due to possible contamination with very small glass particles. Ranbaxy resumed supply of atorvastatin tablets in late-March 2013.
  • Ranbaxy has atorvastatin on shortage due to manufacturing delay.
  • Sandoz could not provide a reason for the shortage.
  • Watson discontinued all atorvastatin presentations in February 2013.

Available Products

Atorvastatin tablets, Apotex
10 mg, 90 count (NDC 60505-2578-09)
10 mg, 1000 count (NDC 60505-2578-08)
20 mg, 90 count (NDC 60505-2579-09)
20 mg, 1000 count (NDC 60505-2579-08)
40 mg, 90 count (NDC 60505-2580-09)
40 mg, 1000 count (NDC 60505-2580-08)
80 mg, 90 count (NDC 60505-2671-09)
80 mg, 1000 count (NDC 60505-2671-08)
 
Atorvastatin tablets, Dr. Reddy’s
10 mg, 90 count (NDC 55111-0121-90)
10 mg, 500 count (NDC 55111-0121-05)
20 mg, 90 count (NDC 55111-0122-90)
20 mg, 500 count (NDC 55111-0122-05)
40 mg, 90 count (NDC 55111-0123-90)
40 mg, 500 count (NDC 55111-0123-05)
80 mg, 90 count (NDC 55111-0124-90)
80 mg, 500 count (NDC 55111-0124-05)
 
Atorvastatin tablets, Major
10 mg, 100 count (NDC 00904-6290-61)
20 mg, 100 count (NDC 00904-6291-61)
 
Atorvastatin tablets, Mylan
10 mg, 90 count (NDC 00378-3950-77)
10 mg, 500 count (NDC 00378-3950-05)
20 mg, 90 count (NDC 00378-3951-77)
20 mg, 500 count (NDC 00378-3951-05)
40 mg, 90 count (NDC 00378-3952-77)
40 mg, 500 count (NDC 00378-3952-05)
80 mg, 90 count (NDC 00378-3953-77)
80 mg, 500 count (NDC 00378-3953-05)
 
Atorvastatin tablets, Mylan Institutional
10 mg, 100 count (NDC 51079-0208-20)
20 mg, 100 count (NDC 51079-0209-20)
40 mg, 100 count (NDC 51079-0210-20)
80 mg, 30 count (NDC 51079-0211-03)
 
Atorvastatin tablets, Sandoz
10 mg, 90 count (NDC 00781-5381-92)
20 mg, 90 count (NDC 00781-5382-92)
80 mg, 90 count (NDC 00781-5388-92)

Atorvastatin tablets, Greenstone
10 mg, 90 count (NDC 59762-0155-01)
10 mg, 1000 count (NDC 59762-0155-02)
20 mg, 90 count (NDC 59762-0156-01)
20 mg, 1000 count (NDC 59762-0156-02)
40 mg, 90 count (NDC 59762-0157-01)
40 mg, 500 count (NDC 59762-0157-02)
80 mg, 90 count (NDC 59762-0158-01)
80 mg, 500 count (NDC 59762-0158-02)

Lipitor tablets, Pfizer
10 mg, 90 count (NDC 00071-0155-23)
10 mg, 100 count (NDC 00071-0155-40)
10 mg, 5000 count (NDC 00071-0155-34)
20 mg, 90 count (NDC 00071-0156-23)
20 mg, 100 count (NDC 00071-0156-40)
20 mg, 5000 count (NDC 00071-0156-94)
40 mg, 90 count (NDC 00071-0157-23)
40 mg, 100 count (NDC 00071-0157-40)
40 mg, 500 count (NDC 00071-0157-73)
40 mg, 2500 count (NDC 00071-0157-88)
80 mg, 64 count (NDC 00071-0158-92)
80 mg, 90 count (NDC 00071-0158-23)
80 mg, 500 count (NDC 00071-0158-73)
80 mg, 2500 count (NDC 00071-0158-88)

Estimated Resupply Dates

  • Apotex has all atorvastatin tablets available, but allocating to customer forecasts.
  • Ranbaxy has all atorvastatin tablets on long term back order and the company cannot estimate a release date.
  • Sandoz has atorvastatin 40 mg tablets on back order with an estimated release date of September 2014.

Related Shortages

Updated

September 16, 2014; September 3, 2014; June 12, 2014; April 25, 2014; April 9, 2014; March 20, 2014; March 12, 2014; February 25, 2014; January 6, 2014; December 19, 2013; December 6, 2013; November 11, 2013; October 30, 2013; October 16, 2013; October 2, 2013; August 27, 2013; August 13, 2013; August 6, 2013; July 25, 2013; July 3, 2013; June 18, 2013; May 15, 2013; May 10, 2013; April 23, 2013; April 3, 2013; March 25, 2013; March 20, 2013; March 8, 2013; February 12, 2013; February 6, 2013; January 18, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement